NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks increased by 3.1% having a strong start to the year. Most notably, CS Medica confirmed its delisting on January 9, and Gubra entered into an agreement with US-based Amylyx Pharmaceuticals to develop a new GLP-1 receptor antagonist. The deal includes milestone payments of MUSD +50 and single-digit royalties on sales. Finally, the most rising stock of the week had a 100% return.
13 of the 22 Danish biotech companies had a positive share price development in the past week and 11 companies had a positive share price performance over the past 12 months. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. 4 Danish healthcare stocks with +100% LTM returns.
Danish company news
No news in the past week
No news in the past week
No news in the past week
No news in the past week
Update from Chairperson: Delisting of CS MEDICA A/S from Spotlight Stock Market (Link)
No news in the past week
No news in the past week
Evaxion announces plan to implement ADS ratio change (Link)
No news in the past week
No news the past week
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor Antagonist (Link)
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
Share price development – Danish stocks
On average, Danish biotech and healthcare stocks delivered a positive return of 2.4%. Please keep in mind that the last trading day of 2024 is included. Fluoguide, Pila Pharma, ExpreS2ion, and ViroGates rose 20-49% although none of the companies reported any news. News was limited across the line with the chairman of CS Medica confirming its delisting on January 9, and Gubra entered into an agreement with US-based Amylyx Pharmaceuticals to develop a new long-acting GLP-1 receptor antagonist. The company will receive an upfront payment, payment for research expenses as well as MUSD +50 in milestone payments.
For the past twelve months, 4 stocks have more than doubled including Pila Pharma, ViroGates, Gubra, and Saniona.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
The Kapital Partner Nordic Healthcare Index (KPHC) increased by 3.1% to 66,05 in the past week. The index had a rough start to the year, but had a strong finish, and even did better than the C25 index. The 1-year return for the KPHC index is almost zero.
The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year
The top three best-performing stocks in the past week
Fluicell AB (96%) conducts research and development in processing the composition of cells in the development of new pharmaceuticals. The company has developed a product portfolio consisting of patented research instruments, which are used to study, analyze, and finally process cells. In addition, there is expertise in 2D / 3D printing. The company got an order worth 1.76 MSEK.
Stenocare AB (67%) specializes in the development of medical cannabis. Stenocare is one of the first players to start selling medicinal cannabis oils in Denmark. In the future, the company will also turn to other European markets with its product range.
Nattaro Labs AB (58%) is a Swedish research and development company focused on the control and elimination of bed bugs. The company is an international bedbug specialist with global collaborations in the remediation industry. The product range includes development and solutions to prevent and control bed bugs.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
